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ECP is well established in the treatment of cGvHD.The mecha-
nism of ECP is unknown, but improvement in the patients has
been correlated with a rise in theT-reg numbers in some studies. Re-
cently the role of B cells in cGvHD has also been reported by Grei-
nex et al. In this study we analyzed the B and T cell numbers and
function in patients undergoing ECP for cGvHD.The study was ap-
proved by the IRB and informed consent obtained. Patients with
cGvHD who had failed prior therapy with steroids or were steroid
dependent or intolerant were enrolled. ECP was performed for
two consecutive days per week for the first 4 weeks and then de-
creased to two treatments every two weeks for the next 12 - 14 weeks.
At that point, if the GvHD was stable or improved, the same fre-
quency of ECPwas continued until 6 months. If there was no impro-
vemen, then the patient was taken off the ECP study.
Comprehensive cGvHD assessments were done by NIH consensus
criteria, at baseline, and then every 2 months for 6 months.These in-
cluded pulmonary function testing, ophthalmology testing, and clin-
ical grading. Blood was taken from the patient from the peripheral
vein as well as from the mononuclear collection from the ECP ma-
chine, prior to the photo-activation. All ECP treatments were
done on the Therakos Celex system. The blood and the mononu-
clear cells were analyzed for T and B cell subset by flow cytometry
for Naive T cells, Central Memory T cells, Effector Memory T cells
and recent thymic emigrants.Plasma was collected and analyzed for
cytokine profile forTh1 andTh2 cytokines. Subsequently themono-
nuclear were cultured and stimulated with anti-CD3 and CD28 an-
tibodies and the cytokine profile will be analyzed. Ten patients havebeen enrolled in the study. All patients are continuing on the ECP
treatment and no patient had to stop the ECP. Patients were on
prednisone and other immunosuppressants at the time of ECP com-
mencement. Data is available on 6 of the 10 patients. ECP therapy
elevated the percentage of CD4 cells that were Tregs. For two pa-
tients, this elevation was not sustained when the frequency of treat-
ment was reduced. The reduction of Tregs in the two patients
correlated perfectly with a reduction in PFT performance. 4/6 pa-
tients saw sustained Treg elevation and no reduction in PFT. B
cell subset analysis showed downward trend in IgD+ memory cells.
These preliminary results show the role of B and T cell in ECP
treated patients and may serve as markers for monitoring response.457
LIMITED BENEFIT OF PENTOSTATIN SALVAGE THERAPY FOR STEROID
REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE
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Corticosteroid refractory (steroid REF) acute graft versus host
disease (A-GVHD) remains one of the major causes of morbidity
and mortality in patients undergoing allogeneic stem cell transplan-
tation (allo-SCT).Multiple agents have been evaluated in this setting
including the purine analog pentostatin but the benefit of adding
pentostatin to ongoing treatment is not well described. We report
a single center experience of pentostatin salvage therapy for steroid
REF A-GVHD. 15 patients received pentostatin as additional treat-
ment of ongoing steroid REF A-GVHD at PMH from Mar 2005-
Mar 2010. Median age was 38 years (Range 21-69). Stem cell source
was PBSC 100%. Matched related donor transplants were per-
formed in 9(60%); 6(40%) underwent unrelated donor transplants.
Conditioning was MA in 11(73%) patients and RIC in 4(27%).
GVHD prophylaxis was cyclosporine in combination with metho-
trexate (n 5 8), MMF (n 5 5), or alemtuzumab (n 5 2). Median
day of development of A-GVHD was 28 days (range 10-56). All pa-
tients had grade III-IVA-GVHD.Thirteen (87%), ten (67%) and six
(40%) patients had GI, skin and liver involvement, respectively. All
patients received steroids as first line treatment. Most patients re-
ceived 1 mg/kg as initial dose but went on to 2 mg/kg on third to
fourth day if no response. Patients who did not respond to methyl-
prednisolone $ 2mg/kg/day for at least 7 days were considered ste-
roid refractory. Eleven (73%) of these patients receive pentostatin as
first line therapy after being deemed steroid refractory. Pentostatin
(1.4 mg/m2 IV) was administered at the median of 53 days after
HSCT (Range 22-240). 10(66%) patients received all 3 doses. Ten
(66%) also received other therapies including mesenchymal stromal
cell investigational product or placebo (n5 5, 33%) at the same time
as part of Osiris study. Other therapies included tacrolimus (n 5 3),
infliximab (n 5 1), MMF (n 5 1), Sirolimus(n 5 1), ATG (n 5 1),
cyclophosphamide(n 5 1). Published criteria from McMillan et al
were used for response assessment. 2 complete responses were seen
(both in skin) but one patient relapsed and did not respond to second
treatment. 3 patients demonstrated PR. 3 out of 5 patients who re-
sponded were involved in Osiris study also. Fourteen died of
GVHD related causes (GI bleed (n 5 1), infections (n 5 5), hepatic
failure (n5 4) and hepatorenal syndrome (n5 4)). One patient is still
alive at last follow up. Pentostatin is of limited benefit in the treat-
ment of steroid refractory acute GVHD.
